Skip to main content
OpenTrials
Completed

NCT Number: NCT03251742

Feasibility and Efficacy of Portable Non-invasive Negative Pressure Ventilation in Fontan Patients

The human heart has 4 chambers: 2 collecting chambers (atria) and 2 pumping chambers (ventricles) to allow blood flow within two distinct circuits: "pulmonary" and "systemic". The pulmonary circuit directs the blood to the lungs to receive oxygen and the systemic circuit delivers oxygen-rich blood throughout the body. In children born with a single ventricle, blood from these two circuits mixes within the heart resulting in lower oxygen levels in the blood delivered to the body (cyanosis).

The Fontan procedure is a palliative surgery which bypasses the need for a ventricle to deliver blood to the lungs, as blood from the body flows passively to the lungs by a man-made connection (whereby two large body veins [cavae] are sewn to the pulmonary arteries), thereby preventing mixing of blood through restoration of two distinct circuits without mixing of blood. Although the Fontan operation effectively eliminates cyanosis and enables survival into adulthood, increased systemic venous pressure is an unavoidable systemic complication and low cardiac output (CO) is pervasive finding.

Despite excellent pediatric surgical results, the risk of late complications and death dramatically increases in the decades following Fontan surgery. A chronically low CO state secondary to decreased forward flow of blood to the lungs can result in end-organ dysfunction and shortened life expectancy. Short of heart transplantation, deemed suitable only for a minority of patients, effective therapies for low CO are largely absent. The investigators aim to investigate a novel, non-invasive, ambulatory therapy which can augment CO. Specifically, external suction is applied intermittently to the chest wall, much like a vacuum, to increase CO, called negative pressure ventilation (NPV) using a Cuirass® ventilator (Hayek Medical). Although used in patients with lung disease, the investigators' proposal is to evaluate this novel, portable, ventilation system would be the first study of its kind in adults with congenital heart disease, specifically those with a Fontan palliation.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

13 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Toronto General Hospital/University of Toronto.

Toronto, Ontario, M5G2N2, Canada

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Fontan patients age > 13 years.

Exclusion criteria

  • unable to complete MRI (pacemaker/defibrillator/retained wires, pregnancy, claustrophobia);
  • evidence of Fontan failure (requiring ongoing medical / device therapy) protein-losing enteropathy, intracardiac thrombus, anatomical obstruction to the Fontan circuit;
  • patent Fontan fenestration;
  • oxygen saturation < 90%;
  • ongoing arrhythmia;
  • ejection fraction < 50% on echocardiography or CMR;
  • moderate or severe valve insufficiency on echocardiography or CMR;
  • Obesity (BMI >35);
  • severe obstructive sleep apnea (AHI>20);
  • chronic obstructive lung disease (FEV1/FVC<60%);
  • severe chest wall deformities (scoliosis, kyphosis, kyphoscoliosis);
  • acute or chronic kidney disease (eGFR<60)
  • unable to provide informed consent.

Treatment and study plan

Hayek RTX ventilator

Device

Negative pressure ventilation in Fontan patients.

Other names: Cuirass, Negative pressure ventilation

Primary outcomes

  1. Efficacy of the NPV on cardiac output

    Time frame: 6-8 months

    Cardiac output will be measured in L/min/m2 using phase contrast MRI. Flow measurements will be made at baseline and with application of the device.

  2. Efficacy of the NPV on organ perfusion

    Time frame: 6-8 months

    Multi organ perfusion will be measured in L/min/m2 using phase contrast MRI. Flow measurements will be made at baseline and with application of the device.

Secondary outcomes

  1. Tolerability and safety of negative pressure ventilation.

    Time frame: 6-8 months

    Assessed by participant questionnaire rating tolerance, safety, overall satisfaction with the device.

Sponsors and collaborators

Lead sponsor

University Health Network, Toronto

Other

Collaborators

  • Hayek Medical

Registry information

Official study title

Feasibility and Efficacy Of Negative Pressure Ventilation in Fontan populatioN: Cardiovascular Flow Assessment by Magnetic Resonance Imaging

Acronym: FONTAN-CMR

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Aug 16, 2017
Registry last updated
Jun 1, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.